Access Infinity, a provider of market access, pricing, and evidence strategy solutions to the global pharmaceutical and biotech industries, has secured an investment from UK-PE firm CBPE Capital to accelerate its next phase of growth. This deal marks the second investment out of CBPE’s Fund XI.
“[CBPE’s] experience and support will be invaluable as we continue to grow our business,” said Shrinivas Rao Mukku and Ahmed Edathodu, founding directors of Access Infinity.
The partnership will enable Access Infinity to enhance its technology platform and accelerate international expansion. It will also support continued investment in talent, innovation, and client services, building on a customer base that already includes 22 of the world’s top 25 pharmaceutical companies.
“We have been hugely impressed by Access Infinity’s expertise, innovation, and client-centric approach,” said Naveen Passi, partner at CBPE.
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies worldwide, providing a suite of software and consulting services that support clients throughout the drug development lifecycle.
CBPE’s investment in Access Infinity was led by Naveen Passi, with support from Rupert Parker, Maximilian O’Connell, Daniel Rossell and Jason Khaksar. Naveen Passi and Rupert Parker will join the board post-completion.
CBPE was advised by Simmons & Simmons (legal), LEK (commercial), PwC (Tax & Structuring), Howden (Insurance), Anthesis (ESG), and Bourne Partners (M&A). Access Infinity was advised by Clearwater (M&A), Squire Patton Boggs (legal), KPMG (financial, tax), Boston Consulting Group (commercial), and Crosslake (technology).
Terms of the transaction were not disclosed.
Press release: Access Infinity Secures Strategic Investment from CBPE to Accelerate its Growth Strategy
